These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26022200)

  • 21. The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern.
    Schaduangrat N; Phanich J; Rungrotmongkol T; Lerdsamran H; Puthavathana P; Ubol S
    J Gen Virol; 2016 Jun; 97(6):1311-1323. PubMed ID: 26935590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.
    Ilyushina NA; Bovin NV; Webster RG; Govorkova EA
    Antiviral Res; 2006 Jul; 70(3):121-31. PubMed ID: 16516984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
    Nguyen JT; Smee DF; Barnard DL; Julander JG; Gross M; de Jong MD; Went GT
    PLoS One; 2012; 7(1):e31006. PubMed ID: 22292088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
    Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
    Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
    Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
    Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
    [No Abstract]   [Full Text] [Related]  

  • 28. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
    Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
    Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
    Wang B; Dwyer DE; Blyth CC; Soedjono M; Shi H; Kesson A; Ratnamohan M; McPhie K; Cunningham AL; Saksena NK
    Antiviral Res; 2010 Jul; 87(1):16-21. PubMed ID: 20385168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo.
    Bhatia S; Lauster D; Bardua M; Ludwig K; Angioletti-Uberti S; Popp N; Hoffmann U; Paulus F; Budt M; Stadtmüller M; Wolff T; Hamann A; Böttcher C; Herrmann A; Haag R
    Biomaterials; 2017 Sep; 138():22-34. PubMed ID: 28550754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
    Wang K; Lei Z; Zhao L; Chen B; Yang F; Liu K; Zhu H; Zhao H; Cao R; Zhang K; Tian Y
    Eur J Med Chem; 2020 Jan; 185():111841. PubMed ID: 31708183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
    Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
    Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
    Zhang J; Murugan NA; Tian Y; Bertagnin C; Fang Z; Kang D; Kong X; Jia H; Sun Z; Jia R; Gao P; Poongavanam V; Loregian A; Xu W; Ma X; Ding X; Huang B; Zhan P; Liu X
    J Med Chem; 2018 Nov; 61(22):9976-9999. PubMed ID: 30365885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
    Park JW; Jo WH
    J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.
    Rameix-Welti MA; Agou F; Buchy P; Mardy S; Aubin JT; Véron M; van der Werf S; Naffakh N
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3809-15. PubMed ID: 16940075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza virus susceptibility and resistance to oseltamivir.
    Aoki FY; Boivin G; Roberts N
    Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
    Hurt AC; Selleck P; Komadina N; Shaw R; Brown L; Barr IG
    Antiviral Res; 2007 Mar; 73(3):228-31. PubMed ID: 17112602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
    Yamada H; Nagao C; Haredy AM; Mori Y; Mizuguchi K; Yamanishi K; Okamoto S
    Antiviral Res; 2014 Nov; 111():69-77. PubMed ID: 25234090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
    Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
    J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses.
    Deng YM; Caldwell N; Hurt A; Shaw T; Kelso A; Chidlow G; Williams S; Smith D; Barr I
    Antiviral Res; 2011 Apr; 90(1):87-91. PubMed ID: 21376084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.